BioNTech (NASDAQ:BNTX) Price Target Increased to $216.00 by Analysts at Morgan Stanley

BioNTech (NASDAQ:BNTX – Get Rating) had its price objective raised by Morgan Stanley from $203.00 to $216.00 in a report released on Tuesday morning, Benzinga reports. They currently have an equal weight rating on the stock.

Other equities analysts have also issued research reports about the company. UBS Group set a $168.00 price target on BioNTech in a research note on Tuesday, November 15th. Canaccord Genuity Group cut their price objective on BioNTech from $200.00 to $191.00 and set a buy rating for the company in a research note on Tuesday, November 8th. Berenberg Bank set a $312.00 price objective on BioNTech in a research note on Tuesday, November 8th. JPMorgan Chase & Co. set a $148.00 price objective on BioNTech in a research note on Wednesday, January 11th. Finally, Bank of America upgraded BioNTech from a neutral rating to a buy rating and set a $239.00 price objective for the company in a research note on Thursday, December 15th. Six analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and an average target price of $209.69.

BioNTech Price Performance

Shares of BioNTech stock opened at $143.85 on Tuesday. The company has a quick ratio of 5.30, a current ratio of 5.37 and a debt-to-equity ratio of 0.01. BioNTech has a twelve month low of $117.08 and a twelve month high of $189.07. The business has a 50-day moving average price of $159.79 and a 200 day moving average price of $152.33. The firm has a market cap of $34.91 billion, a PE ratio of 3.25 and a beta of 0.26.

BioNTech (NASDAQ:BNTX – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The company reported $7.04 earnings per share for the quarter, beating the consensus estimate of $3.66 by $3.38. BioNTech had a return on equity of 66.45% and a net margin of 55.72%. The firm had revenue of $3.46 billion during the quarter, compared to analyst estimates of $1.90 billion. During the same quarter in the previous year, the business earned $14.56 EPS. BioNTech’s revenue for the quarter was down 43.1% compared to the same quarter last year. Sell-side analysts predict that BioNTech will post 36.23 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of large investors have recently made changes to their positions in the stock. Captrust Financial Advisors lifted its holdings in BioNTech by 6.9% in the second quarter. Captrust Financial Advisors now owns 1,068 shares of the company’s stock valued at $159,000 after acquiring an additional 69 shares during the last quarter. Centaurus Financial Inc. lifted its holdings in BioNTech by 5.2% in the first quarter. Centaurus Financial Inc. now owns 1,448 shares of the company’s stock valued at $247,000 after acquiring an additional 71 shares during the last quarter. Green Alpha Advisors LLC lifted its holdings in BioNTech by 2.9% in the fourth quarter. Green Alpha Advisors LLC now owns 3,406 shares of the company’s stock valued at $512,000 after acquiring an additional 97 shares during the last quarter. Midwest Professional Planners LTD. lifted its holdings in BioNTech by 6.0% in the third quarter. Midwest Professional Planners LTD. now owns 1,885 shares of the company’s stock valued at $254,000 after acquiring an additional 106 shares during the last quarter. Finally, National Bank of Canada FI lifted its holdings in BioNTech by 21.3% in the fourth quarter. National Bank of Canada FI now owns 655 shares of the company’s stock valued at $98,000 after acquiring an additional 115 shares during the last quarter. 15.29% of the stock is currently owned by hedge funds and other institutional investors.

About BioNTech

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.